.avif)
.avif)
Bridgebio Email Format
Biotechnology Research
・
501-1,000 employees
・
Palo Alto, CA, USA
BridgeBio is a biotechnology company focused on discovering and developing transformative medicines for patients living with genetic diseases and cancers.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
first.last@bridgebio.com
Company Overview
Industry
Biotechnology Research
Founded
2014
Headquarters
Palo Alto, CA, USA
Revenue
$250M-$500M
FUNDING Stage
Public
Website
Key Executives
Neil Kumar (Chief Executive Officer), Thomas Trimarchi, Ph.D. (President and Chief Financial Officer), Matt Outten (Chief Commercial Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Bridgebio?
Bridgebio uses the first.last format on bridgebio.com, so Jane Smith would be jane.smith@bridgebio.com.
What approved medicines has Bridgebio brought to market?
Bridgebio has two approved medicines: Attruby (acoramidis) for transthyretin amyloid cardiomyopathy and NULIBRY (fosdenopterin) for a rare genetic disease. Acoramidis is also approved outside the US under the name Beyonttra.
How does Bridgebio Oncology Therapeutics relate to Bridgebio?
Bridgebio Oncology Therapeutics, known as BBOT, was initially formed as a subsidiary of Bridgebio and completed a $200 million private financing with external investors in 2024 to advance its precision oncology pipeline targeting RAS-dependent cancers.
Who leads Bridgebio as its chief executive officer?
Neil Kumar is the CEO of Bridgebio. Thomas Trimarchi serves as President and CFO, and Matt Outten holds the role of Chief Commercial Officer. You can use Clay to find and verify direct contact details for Bridgebio's leadership team.
Which rare disease programs does Bridgebio currently have in Phase 3 clinical trials?
Bridgebio has several Phase 3 programs underway, including BBP-418 for Limb-Girdle Muscular Dystrophy Type 2I, encaleret for Autosomal Dominant Hypocalcemia Type 1, and infigratinib for achondroplasia, all targeting patients with defined genetic conditions.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating